Page last updated: 2024-11-12
js399-19
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
phenamacril: an effective agent against several fungi species belonging to the Fusarium genus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10632495 |
SCHEMBL ID | 230664 |
MeSH ID | M0534964 |
Synonyms (12)
Synonym |
---|
39491-78-6 |
SCHEMBL230664 |
phenamacril |
2-propenoic acid, 3-amino-2-cyano-3-phenyl-, ethyl ester, (2z)-; 2-propenoic acid, 3-amino-2-cyano-3-phenyl-, ethyl ester, (z)- (9ci); ethyl (2z)-3-amino-2-cyano-3-phenylprop-2-enoate; ethyl (z)-3-amino-2-cyano-3-phenylprop-2-enoate; phenamacril; phenamac |
ethyl (z)-3-amino-2-cyano-3-phenylprop-2-enoate |
js399-19 |
ethyl (z)-3-amino-2-cyano-3-phenylacrylate |
q8v , |
ethyl (2z)-3-amino-2-cyano-3-phenylprop-2-enoate |
3-amino-2-cyano-3-phenyl-2-propenoic acid ethyl ester |
(z)-ethyl 3-amino-2-cyano-3-phenylacrylate |
AKOS040745904 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (21.43) | 24.3611 |
2020's | 11 (78.57) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |